Have you incorporated the PCA3 urine test into your practice to help you decide whether to recommend repeat prostate biopsies?

Share this content:

The FDA approved the PCA3 urine test in February 2012 to be used in conjunction with other patient information to help clinicians determine if men who have had a previous negative prostate biopsy should undergo a repeat biopsy.

Although PCA3 has lower sensitivity than PSA, it has higher specificity for prostate cancer as well as superior positive and negative predictive values. Some 20%-40% of men who had initial negative biopsy are found to have an abnormal biopsy on repeat testing.

Renal & Urology News would like to know how urologists have embraced the PCA3 urine test, so please answer the following poll question:

Leave a comment below to explain your choice.

You must be a registered member of Renal and Urology News to post a comment.

Sign Up for Free e-newsletters